These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36569901)

  • 21. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
    Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
    Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
    Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
    J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
    Zekri L; Hagelstein I; Märklin M; Klimovich B; Christie M; Lindner C; Kämereit S; Prakash N; Müller S; Stotz S; Maurer A; Greve C; Schmied B; Atar D; Rammensee HG; Jung G; Salih HR
    Sci Transl Med; 2024 Mar; 16(737):eadh1988. PubMed ID: 38446900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
    Beum PV; Lindorfer MA; Taylor RP
    J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
    Funakoshi S; Longo DL; Murphy WJ
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
    Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
    Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.
    Evers M; Ten Broeke T; Jansen JHM; Nederend M; Hamdan F; Reiding KR; Meyer S; Moerer P; Brinkman I; Rösner T; Lebbink RJ; Valerius T; Leusen JHW
    MAbs; 2020; 12(1):1795505. PubMed ID: 32744145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
    Waldhauer I; Gonzalez-Nicolini V; Freimoser-Grundschober A; Nayak TK; Fahrni L; Hosse RJ; Gerrits D; Geven EJW; Sam J; Lang S; Bommer E; Steinhart V; Husar E; Colombetti S; Van Puijenbroek E; Neubauer M; Cline JM; Garg PK; Dugan G; Cavallo F; Acuna G; Charo J; Teichgräber V; Evers S; Boerman OC; Bacac M; Moessner E; Umaña P; Klein C
    MAbs; 2021; 13(1):1913791. PubMed ID: 33974508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
    Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
    Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
    Winiarska M; Bil J; Wilczek E; Wilczynski GM; Lekka M; Engelberts PJ; Mackus WJ; Gorska E; Bojarski L; Stoklosa T; Nowis D; Kurzaj Z; Makowski M; Glodkowska E; Issat T; Mrowka P; Lasek W; Dabrowska-Iwanicka A; Basak GW; Wasik M; Warzocha K; Sinski M; Gaciong Z; Jakobisiak M; Parren PW; Golab J
    PLoS Med; 2008 Mar; 5(3):e64. PubMed ID: 18366248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis.
    Chen Y; Chen L; Lu Q; Meng Y; Wang C; Wang L; Wang H; Yu X; Zhang Y; Zhao L; Li B; Guo Y
    Biochem Biophys Res Commun; 2015 Apr; 459(4):617-22. PubMed ID: 25749344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.